Difference between revisions of "Motixafortide (Aphexda)"
Jump to navigation
Jump to search
m |
m |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
| + | ==Mechanism of action== | ||
cyclic-peptide CXCR4 inhibitor | cyclic-peptide CXCR4 inhibitor | ||
| + | *[https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10679 IUPHAR/BPS] | ||
| + | ==History of changes in FDA indication== | ||
| + | *2023-09-12: Approved for the mobilization of hematopoietic stem cells to peripheral blood prior to collection for autologous stem cell transplantation (ASCT) in patients with multiple myeloma. ''(Based on GENESIS)'' | ||
| + | |||
| + | ==Also known as== | ||
| + | *'''Code names:''' BKT-140, BL-8040, TF-14016 | ||
| + | *'''Brand name:''' Aphexda | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Latest revision as of 15:23, 17 November 2023
Mechanism of action
cyclic-peptide CXCR4 inhibitor
History of changes in FDA indication
- 2023-09-12: Approved for the mobilization of hematopoietic stem cells to peripheral blood prior to collection for autologous stem cell transplantation (ASCT) in patients with multiple myeloma. (Based on GENESIS)
Also known as
- Code names: BKT-140, BL-8040, TF-14016
- Brand name: Aphexda